#1 Clinical Trials Search in Europe

Heparin Calcium

Clinical trials investigating Heparin Calcium are studying treatment strategies for people with acute venous thromboembolism who are also taking antiplatelet medicines. These trials aim to compare safety and bleeding risk, especially when full-dose anticoagulant therapy is used alone or together with antiplatelet therapy. The main study shown here is in adults with acute VTE.

Table of Contents

Trial overview

The main clinical trial listed for Heparin Calcium is NCT05627375, also called BAT-VTE, which studies the best antithrombotic treatment in patients with acute venous thromboembolism who are taking antiplatelet therapy.[1]

This is an interventional study, which means researchers assign treatments and compare outcomes between groups.[1]

Who is being studied

The trial targets people with an acute venous thromboembolism event, which means a new blood clot in a vein.[1]

It focuses on patients who are also taking antiplatelet medicine for secondary arterial prevention at the time the venous clot is diagnosed.[1]

Treatments being compared

The study compares full-dose anticoagulant therapy alone with a combination of antiplatelet therapy and full-dose anticoagulant therapy.[1]

The trial lists several study medicines, including Heparin Calcium as part of the anticoagulant options used in the study setting.[1]

Other listed medicines include apixaban, warfarin, fondaparinux, dalteparin, tinzaparin, enoxaparin, acenocoumarol, and rivaroxaban, showing that the study compares multiple treatment approaches used in practice.[1]

Study phase and size

The trial is in Phase 3, which is a later stage of research that tests treatment strategies in a larger group of patients.[1]

The planned enrollment is 1,400 participants.[1]

Outcomes being measured

The main outcome is clinically relevant bleeding, which combines major bleeding and clinically relevant non-major bleeding using ISTH definitions.[1]

This bleeding outcome is measured at the end of the full-dose treatment period, or for up to 12 months.[1]

The brief study aim is to show whether full-dose anticoagulant therapy alone is better than combining anticoagulant and antiplatelet therapy for lowering bleeding risk in this patient group.[1]

What this means for patients

For patients, this trial is mainly about finding the safest treatment plan after a new venous blood clot when antiplatelet medicine is already being used.[1]

The study does not focus on symptom relief alone; it focuses on whether one treatment strategy causes less important bleeding than another.[1]

Because the trial is in Phase 3 and includes a large number of participants, it is designed to give stronger evidence about which treatment approach may be safer in this situation.[1]

Trial ID Phase Condition studied Status Enrollment
NCT05627375 Phase 3 Acute venous thromboembolism event in patients taking antiplatelets Authorised 1400

FAQ

  • What is being studied in Heparin Calcium clinical trials? The trial is studying treatment choices for acute venous thromboembolism in people already taking antiplatelet medicine. It looks at bleeding risk when full-dose anticoagulant therapy is used alone or with antiplatelet therapy.
  • Who can take part in this trial? The target group is patients with an acute venous thromboembolism event who are receiving antiplatelet treatment for secondary arterial prevention. The trial is focused on adults in this situation.
  • What phase is the trial? The study is in Phase 3. This means it is a later-stage trial that compares treatment strategies in a larger group of patients.
  • What outcome is the trial measuring? The main outcome is clinically relevant bleeding. This includes major bleeding and clinically relevant non-major bleeding, measured by the end of the full-dose treatment period or up to 12 months.
  • How many people are planned for the study? The planned enrollment is 1,400 people. This gives the study enough participants to compare the treatment groups.

Ongoing Clinical Trials on Heparin Calcium

  • Study on the Best Antithrombotic Therapy for Patients with Acute Venous Thromboembolism Using Tinzaparin Sodium and Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Acute venous thromboembolism: A sudden blood clot in a vein. It can include deep vein thrombosis or a clot that travels to the lungs.
  • Antiplatelet therapy: Treatment with medicine that helps stop blood cells called platelets from clumping together. It is often used to prevent artery-related events.
  • Secondary arterial prevention: Treatment used to help prevent another artery-related event after someone has already had one.
  • Anticoagulant therapy: Treatment that helps prevent blood clots from growing or forming. In the trial, this is given at full dose.
  • Full-dose treatment period: The time when the study medicine is given at the planned full treatment dose.
  • Clinically relevant bleeding: Bleeding that matters medically and may need attention. In this study, it includes major bleeding and clinically relevant non-major bleeding.
  • Major bleeding: Serious bleeding that can be dangerous and usually needs urgent medical care.
  • Clinically relevant non-major bleeding: Bleeding that is not classed as major, but is still important enough to be tracked in a trial.
  • ISTH: A medical group whose bleeding definitions are often used in research. It helps trials measure bleeding in a standard way.
  • Phase 3: A late stage of clinical research that compares treatments in a larger group of patients.
  • Enrollment: The number of people planned to join a study.

References